• Avacta presented an AGM business update highlighting pipeline progress across three pre|CISION oncology programs.
• AVA6103 Phase 1 FOCUS-01 began dosing in March following January IND clearance; initial clinical data targeted for late H2 2026.
• AVA6000 Phase 1a/1b update showed early efficacy signals in salivary gland cancers; regulators lifted the lifetime maximum dose on cardiac safety.
• March placing raised GBP 10 million, extending cash runway into early Q1 2027; June raise added about GBP 9 million to cut Convertible Bond debt.
• Board changes featured Richard Hughes as non-executive chairman; an additional non-executive director appointment is being finalized.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avacta Group plc published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.